Polycystic ovary syndrome affects 8–13% of reproductive-age women. Insulin resistance is central to its pathophysiology. GLP-1 receptor agonists — by improving insulin sensitivity and reducing weight — address the metabolic core of PCOS, and emerging evidence shows clinical benefit on cycle regularity, ovulation, and metabolic markers.

Why GLP-1 makes sense in PCOS

PCOS is characterized by:

Insulin resistance — present in 70–80% of PCOS patients regardless of weight.
Hyperandrogenism — driven in part by insulin's stimulation of ovarian androgen production.
Anovulation — driven by disordered GnRH pulsatility and elevated insulin/IGF-1.
Long-term metabolic risk — elevated T2D, CVD, MASLD risk.

GLP-1 receptor agonists improve insulin sensitivity, reduce body weight, and (downstream) reduce ovarian androgen production. The mechanism aligns directly with PCOS pathophysiology.

The evidence — small but consistent

PCOS-specific phase 3 trial data are limited but accumulating. Several smaller randomized trials and observational cohorts show:

Weight reduction comparable to non-PCOS obesity populations (10–20% with semaglutide; higher with tirzepatide).
Cycle regularization in a meaningful proportion of patients with prior anovulation.
Restoration of ovulation in patients with weight-related anovulation.
Reductions in fasting insulin, HOMA-IR, and total testosterone.

Larger trials (PCOS-specific phase 3 programs) are not yet running, but the off-label use is common and supported by mechanism.

The fertility consideration

This is the most consequential clinical issue. GLP-1 therapy frequently restores ovulation in patients with weight-related anovulation — including patients who had been previously infertile. The combination of "I started GLP-1 therapy and unexpectedly conceived" is well documented in PCOS practice.

Practical implications:

If pregnancy is desired: GLP-1 may be an effective ovulation-induction adjunct, but should be stopped ≥2 months (semaglutide) or ≥1 month (tirzepatide) before attempting conception.
If pregnancy is not desired: reliable contraception is essential throughout treatment. Patients who had assumed they could not conceive due to long-standing infertility need this discussion.

Hirsutism and androgen effects

Improvements in hirsutism on GLP-1 therapy are typically modest and slow. The dominant driver is reduction in fasting insulin → reduced ovarian androgen production. Patients with significant hirsutism should not expect rapid cosmetic improvement; the benefit is gradual and is one piece of a broader treatment plan that may include anti-androgens (spironolactone) and laser/electrolysis.

How PCOS-specific telehealth fits

Most compounded GLP-1 telehealth programs we review market primarily for weight management, not for PCOS-specific care. Patients with PCOS considering compounded GLP-1 should:

Discuss the off-label nature of PCOS-specific treatment with their prescriber.
Confirm contraception strategy if pregnancy is not desired.
Maintain coordination with their gynecologist or endocrinologist for cycle and androgen monitoring.
Plan for the possibility that ovulation may resume — practical consequences for relationships and family planning.

What about metformin and other PCOS therapies?

Metformin has been the standard insulin-sensitizing agent in PCOS for decades. Effect sizes on weight, cycle regularity, and ovulation are modest. GLP-1 receptor agonists appear meaningfully more effective on these endpoints, especially when weight is a contributing factor. Combination metformin + GLP-1 is common; consider this with the prescriber.